Innate Pharma SA (Euronext Paris: IPH) (Nasdaq: IPHA), an oncology-focused biotech company, on Wednesday reported the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with healthcare company Sanofi.
This licensing agreement is now effective, under which Sanofi is licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate's ANKET (Antibody-based NK Cell Engager Therapeutics) platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
Also, Sanofi has the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialisation.
Under the terms of the agreement, Innate said it will receive EUR25m upfront payment and up to EUR1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates